Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 24 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.92 Insider Own14.29% Shs Outstand115.76M Perf Week-4.87%
Market Cap1.13B Forward P/E- EPS next Y-1.24 Insider Trans-0.86% Shs Float99.22M Perf Month10.02%
Income-217.42M PEG- EPS next Q-0.51 Inst Own98.42% Short Float21.51% Perf Quarter11.78%
Sales106.39M P/S10.63 EPS this Y55.09% Inst Trans9.75% Short Ratio7.33 Perf Half Y133.17%
Book/sh1.95 P/B5.02 EPS next Y27.00% ROA-50.68% Short Interest21.34M Perf Year-5.15%
Cash/sh3.49 P/C2.80 EPS next 5Y9.80% ROE-119.24% 52W Range1.76 - 13.17 Perf YTD202.48%
Dividend Est.- P/FCF- EPS past 5Y-48.07% ROI-50.45% 52W High-25.82% Beta1.18
Dividend TTM- Quick Ratio9.61 Sales past 5Y303.42% Gross Margin92.35% 52W Low455.11% ATR (14)0.72
Dividend Ex-Date- Current Ratio9.89 EPS Y/Y TTM48.75% Oper. Margin-184.65% RSI (14)50.80 Volatility6.11% 8.05%
Employees296 Debt/Eq0.92 Sales Y/Y TTM1545.18% Profit Margin-204.36% Recom1.33 Target Price19.17
Option/ShortYes / Yes LT Debt/Eq0.92 EPS Q/Q75.67% Payout- Rel Volume0.48 Prev Close10.20
Sales Surprise226.65% EPS Surprise53.28% Sales Q/Q1682.42% EarningsMay 14 AMC Avg Volume2.91M Price9.77
SMA20-2.03% SMA507.49% SMA20045.36% Trades Volume1,396,611 Change-4.22%
Date Action Analyst Rating Change Price Target Change
Jan-03-24Upgrade Mizuho Neutral → Buy $4 → $8
Oct-26-23Downgrade Mizuho Buy → Neutral $57 → $4
Oct-13-23Downgrade Goldman Buy → Neutral $32 → $6
Sep-07-22Initiated Needham Buy $46
Mar-17-22Initiated Goldman Buy $45
Jun-30-21Initiated Mizuho Buy $58
May-27-21Upgrade Morgan Stanley Equal-Weight → Overweight $52
Nov-09-20Upgrade Goldman Neutral → Buy $34 → $36
Oct-08-20Initiated Truist Buy $38
Feb-25-20Initiated Guggenheim Buy $36
Jul-23-24 08:00AM
Jul-22-24 08:00AM
Jul-19-24 09:40AM
Jul-17-24 09:54AM
Jul-10-24 01:13PM
11:23AM Loading…
Jul-09-24 04:53PM
Jul-06-24 08:00AM
Jul-03-24 04:00PM
Jul-02-24 07:45AM
Jun-17-24 09:40AM
Jun-14-24 09:55AM
Jun-13-24 06:00AM
02:30PM Loading…
Jun-10-24 02:30PM
Jun-05-24 04:00PM
Jun-03-24 08:00AM
May-31-24 09:40AM
May-20-24 09:55AM
May-16-24 11:23AM
May-15-24 12:54PM
03:13AM Loading…
May-14-24 08:57PM
May-13-24 08:00AM
May-03-24 04:00PM
Apr-29-24 04:00PM
Apr-10-24 08:00AM
Apr-05-24 04:00PM
Apr-01-24 07:00AM
Mar-28-24 08:00AM
Mar-19-24 09:55AM
Mar-18-24 09:55AM
Mar-11-24 08:00AM
Mar-10-24 04:00PM
Mar-09-24 04:00PM
Mar-08-24 07:33PM
Mar-05-24 04:00PM
Mar-04-24 04:00PM
Mar-01-24 09:55AM
Feb-29-24 05:00PM
Feb-28-24 11:30PM
Feb-27-24 08:11AM
Feb-16-24 08:00AM
Feb-06-24 04:00PM
Feb-01-24 03:04PM
Jan-31-24 08:00AM
Jan-29-24 08:00AM
Jan-22-24 08:00AM
Jan-18-24 12:00PM
Jan-14-24 04:00AM
Dec-23-23 07:32PM
Dec-19-23 11:48AM
Dec-18-23 06:02AM
Dec-15-23 05:19PM
Dec-01-23 10:00PM
Nov-29-23 08:00AM
Nov-17-23 09:35AM
Nov-16-23 11:04PM
Nov-15-23 01:26PM
Nov-14-23 05:04PM
Nov-05-23 03:55PM
Nov-03-23 09:47AM
Nov-02-23 04:00PM
Nov-01-23 09:35AM
Oct-31-23 09:35AM
Oct-26-23 12:32PM
Oct-25-23 04:00PM
Oct-20-23 08:00AM
Oct-19-23 11:45PM
Oct-13-23 08:00AM
Oct-09-23 08:52AM
Oct-06-23 08:00AM
Oct-05-23 04:00PM
Sep-27-23 08:00AM
Sep-25-23 04:17PM
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Welgus Howard G.DirectorJul 01 '24Option Exercise1.6810,00016,806190,339Jul 02 07:13 PM
Welgus Howard G.DirectorJul 01 '24Sale9.3110,00093,141180,339Jul 02 07:13 PM
Welgus Howard G.DirectorJun 04 '24Option Exercise1.6810,00016,806180,200Jun 06 04:15 PM
Welgus Howard G.DirectorJun 04 '24Sale8.0110,00080,092170,200Jun 06 04:15 PM
Burnett PatrickSee RemarksMay 30 '24Option Exercise0.0023,0000232,793May 31 04:50 PM
Burnett PatrickSee RemarksMay 30 '24Sale8.7523,000201,319209,793May 31 04:50 PM
Burnett PatrickSee RemarksMay 29 '24Sale8.7249,952435,387209,793May 31 04:50 PM
Matsuda MasaruSee RemarkMay 28 '24Sale9.011,77515,988188,508May 29 07:38 PM
Edwards Larry ToddSVP Chief Commercial OfficerMay 17 '24Sale8.987,64068,582140,360May 20 05:12 PM
Watanabe Todd FranklinSee RemarksMay 02 '24Sale8.7413,783120,433860,750May 03 04:22 PM
Burnett PatrickSee RemarksMay 02 '24Sale8.749,55583,490259,745May 03 04:22 PM
Matsuda MasaruSee RemarkMay 02 '24Sale8.745,01643,829185,408May 03 04:22 PM
Moore Matthew RichardSVP and Chief Business OfficerMay 02 '24Sale8.744,68140,902145,505May 03 04:29 PM
Heron Patrick JDirectorMar 04 '24Buy9.5021,052199,9948,785,284Mar 06 04:28 PM
Watanabe Todd FranklinSee RemarksMar 04 '24Sale11.1214,903165,739874,533Mar 06 05:09 PM
Burnett PatrickSee RemarksMar 04 '24Sale11.124,78253,182269,300Mar 06 05:12 PM
Matsuda MasaruSee RemarkMar 04 '24Sale11.123,76041,816190,424Mar 06 05:14 PM
Moore Matthew RichardSVP and Chief Business OfficerMar 04 '24Sale11.123,46838,568146,020Mar 06 05:08 PM
Watanabe Todd FranklinSee RemarksFeb 28 '24Sale10.602,46526,129889,436Mar 01 04:11 PM
Burnett PatrickSee RemarksJan 02 '24Sale3.541,3254,69257,032Jan 03 05:30 PM
Watanabe Todd FranklinSee RemarksDec 01 '23Option Exercise1.6859,525100,038513,682Dec 01 08:51 PM
Matsuda MasaruSee RemarkNov 21 '23Sale1.981,8503,66146,634Nov 21 05:47 PM
Frazier Life Sciences VIII, L.10% OwnerOct 24 '23Buy2.5080,000200,0008,764,232Oct 26 04:09 PM
Burnett PatrickSee RemarksAug 21 '23Sale7.041,60511,30258,357Aug 22 12:24 PM